TRI-611 is an oral investigational small molecule therapy designed as a potent, brain-penetrant molecular glue degrader, engaging the body’s innate protein-degradation machinery to target ALK fusion ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results